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Objective: Little is known about telomere dynamics in keloids. As keloid formation is
dependent on cell replication, in theory telomeres should be shorter in keloids than in
normal skin. We examined this concept in the present study. Methods: We measured
by Southern blot analysis telomere length in keloids and in adjacent normal skin of 16
individuals. When available, we also measured telomere length in blood (leukocytes)
and subcutaneous fat. Results: Telomere length was highly variable among individuals
but highly correlated among tissues (cells) within the individual. The mean telomere
length in the keloids was longer than that in the adjacent normal skin and displayed
a length gradient, with the mean length of telomeres shorter just below the epidermis
and longer at the base of the keloids. No apparent telomerase activity was detected in
the keloids. Conclusions: Our ﬁndings suggest a transient activation of telomerase, the
reverse transcriptase that prevents telomere shortening, probably during the early phase
of keloid formation. The activation of telomerase serves to maintain (or even elongate)




for example, those of recent African or Asian origins, are more prone to keloids than fair-
skinned whites of European ancestry.1,2 These ﬁbro-proliferative tumors are more common
in adolescents and young adults than in older persons and they occur more frequently in the
head, neck and trunk than in the lower extremities. Keloids display a high recurrence rate
postresection and there are no effective modalities for their prevention (short of avoiding
skin injury) in individuals at risk. Various medical treatments to prevent keloid recurrence
after resection have been employed with only limited success.1,2
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The histology and composition of keloids have been well-characterized, but their
pathogenesis is poorly understood, perhaps because there is no animal model for keloid
formation.3 Keloid composition includes ﬁbroblasts, inﬂammatory cells, an abundance of
extracellularmatrix,primarilycollagen,andsupportivevascularnetwork.Previousresearch
suggests the potential role of cytokines, principally interleukin 6 (IL-6),4 transforming
growth factor beta (TGFβ),5,6 and mesenchymal stem cells7 in keloid pathogenesis.
Keloid formation or, for that matter, any wound healing depends on cell proliferation.
As somatic cells replicate, their telomeres, the TTAGGG tandem repeats at the ends of
chromosomes, undergo progressive shortening.8,9 Thus, telomere shortening is an index of
the replicative history of somatic cells, unless mechanisms that counteract telomere short-
ening are activated. One of these is the activation of telomerase—a reverse transcriptase
that adds telomere repeats to the ends of chromosomes9; the other is referred to as the alter-
native lengthening of telomeres (ALT).10 Accordingly, understanding telomere dynamics
in keloids, which can become quite large, might shed light on potential mechanisms that
sustain their growth over and above that of a normal wound healing. We explored this
concept in the present work by measuring telomere lengths in keloids.
METHODS
Subjects
We measured telomere length in keloids, in adjacent normal skin, and, when available, in
subcutaneous fat and blood (leukocyte) samples from 16 individuals. They included 13
African Americans, 2 Hispanics, and 1 Asian; 8 males and 8 females, with age range from
14 to 58 years.
Keloid resection and sampling of subcutaneous fat and blood
Most keloids were resected under local anesthesia. The lesion was removed with mini-
mal injury to adjacent normal skin. In some cases, keloids were removed under general
anesthesia. In that setting, the anesthesiologist obtains a blood sample while inserting an
intravenous catheter. Subcutaneous fat tissue was obtained only when fat was exposed in
the operative ﬁeld.
Measurements of telomere length and telomerase activity
DNA was extracted by phenol/chloroform and telomere length was measured by Southern
blot analysis of the terminal restriction fragments (TRFs).11 All DNA samples were sub-
jected to integrity testing; no sample displayed evidence of DNA degradation. Telomerase
activity was measured by the TRAP assay (TRAPeze Telomerase Detection kit, Millipore,
California). In 9 keloids, we mapped telomere length in 3 distinct regions: the most distant
area from the surgical excision, just below the epidermis (keloid 1); area adjacent to the
normal skin at the base of the keloid (keloid 2); and the center of the base of the keloid
(keloid 3). The remaining 7 keloids were small and the entire keloid was used to measure
telomere length.
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As noted earlier, we obtained keloid and skin samples from the 16 participants but
could not always obtain a complete set of samples (including keloid, skin, subcutaneous
fat, and blood).
Statistical analysis
We used the mixed procedure in SAS 9.1 to perform repeated-measures ANOVA. Results
from all participants were used for analyses, unless otherwise indicated. We assumed
unstructuredcorrelationsbetweenmeasureswithinthesameindividualtocomparetelomere
lengths in different tissues or keloid regions. The model comparing skin and keloids used
thefollowingcategories:keloid(inthecasethattheentirekeloidwasused),keloid1,keloid
2, or keloid 3 as deﬁned earlier. Least square means and conﬁdence intervals (CIs) from
the model are presented. A contrast was used to compare the mean telomere length in skin
to keloids; since we had a single keloid sample for some patients but up to 3 samples from
different regions of the tumor for others, we performed a 2-df test contrasting the mean
telomere length in skin to that in the single keloid sample and the mean telomere length
in skin to the average of means from the 3 keloid regions. A subset analysis of those who
provided samples from 3 keloid regions was also conducted to conﬁrm results. We also
performed a less conservative test comparing skin and keloid by ﬁtting a model with an
indicator of whether a sample came from skin or keloid, assuming a compound symmetry
correlation structure, and then compared telomere length in skin to keloids using a 1-df
test. Pairwise comparisons were conducted to identify differing categories.
All testing was 2-sided and conducted at the 5% signiﬁcance level.
Informed consent
All participants provided written informed consents approved by the institutional review
board of the University of Medicine and Dentistry of New Jersey, New Jersey Medical
School.
RESULTS
Figure 1 illustrates typical Southern blots analysis of the TRFs from subcutaneous fat,
normal skin, 3 regions in the keloid (keloid 1, keloid 2, and keloid 3) and blood samples of
a single individual.
Figure 2 shows telomere length in subcutaneous fat, normal skin, and blood from the
16 study participants. The mean telomere length in subcutaneous fat, 8.32 kb (95% CI:
7.84–8.81) was longer than that in skin, 7.29 kb (95% CI: 6.85–7.73), and blood, 7.05 kb
(95% CI: 6.49–7.61), and the differences were statistically signiﬁcant (P < .001), but there
was no difference in mean telomere length between skin and blood (P = .27). Models
that further adjusted for age and whether the participant was African American did not
qualitatively change the estimated telomere lengths or conclusions comparing lengths in
skinandkeloids.Youngerage(P =.077)andAfricanAmericans(P =.090)hadmarginally
signiﬁcant longer mean telomere lengths in the 3 tissues. We could not formally test for
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differences in telomere lengths in tissues by age and being African American because of
the small sample size.
Figure 1. Southern blots of
the terminal restriction frag-
ments. The source of the
DNAandthemeanlength(in
kb) of the terminal restric-
tion fragments are indicated
at the bottom of each lane.
The molecular-weight refer-
ence ladder is shown in the
fourth lane from the left.
Figure 3 displays the relation of telomere lengths between normal skin and blood,
between normal skin and subcutaneous fat, and between blood and subcutaneous fat. The
interindividual variation in telomere length among participants amounted to approximately
3 to 3.5 kb. However, relative synchrony in telomere length was found for these tissues
within the individual so that a person who had long (or short) telomeres in one tissue
tended to have long (or short) telomeres in other tissues. Pairwise scatterplots of telomere
lengths did not always fall along the 45˚ line, which would suggest equal lengths in tissues;
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speciﬁcally, comparisons of lengths in fat to the other tissues show that telomeres in fat
are generally longer than lengths in skin or blood, consistent with the results from the
repeated-measures ANOVA.
Figure 2. Telomere length in subcutaneous blood, fat, and skin in pa-
tientswithkeloids.Broadhorizontallinesarethemeantelomerelengths
and vertical bars are 95% conﬁdence intervals based on repeated-
measures analysis. Omnibus test of any difference by tissue type: P <
.001. Fat is signiﬁcantly different from both blood and skin (both P <
.001), but blood and skin are not signiﬁcantly different from each other
(P = .27).
Figure 3. Synchrony in telomere length. Skin vs blood (left panel); blood vs subcutaneous fat
(middle panel); and skin vs subcutaneous fat (right panel). Pearson correlations are shown, P value
test whether the correlation = 0.
Figure 4 shows the relation between telomere lengths in normal skin specimens and in
keloids. The least square means (95% CI) for telomere length in normal skin was 7.29 kb
(6.85–7.73), at keloid 1 was 7.32 kb (6.94–7.69), at keloid 2 was 7.66 kb (7.25–8.06), and
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at keloid 3 was 7.80 kb (7.43–8.16) and for those in which telomere length was measured
using the entire keloid was 7.56 kb (7.11–8.00). The overall test was signiﬁcant (P = .029),
suggesting a difference within the keloid regions or between the normal skin and one of the
keloid regions. There was no evidence of telomere shortening in the keloid compared with
normal skin. In fact, there was a tendency for a longer telomere length in keloid tissue than
in the adjacent normal skin. Pairwise comparisons suggest that the mean telomere length
at keloid 3, sampled from the base of the keloid, was longer than both adjacent normal
skin and keloid 1. Keloid 1 and keloid 2 were also signiﬁcantly different. Telomere length
showed the following pattern: normal skin < keloid 1 < keloid 2 < keloid 3. A subgroup
analysisof thosepatientswith results from skin and each of the three keloidregionsshowed
a similar pattern.
Figure 4. Telomere length in normal skin and in keloid samples. Normal skin, different
regions in keloids when available; keloid 1 (K-1), keloid 2 (K-2), and keloid 3 (K-3) or the
entirekeloid,whentheentirekeloidwasusedtodeterminetelomerelength.Broadhorizontal
lines are the mean telomere lengths and vertical bars are 95% conﬁdence intervals based
on repeated-measures analysis. Omnibus test comparing the mean telomere lengths in the 5
categories: P = .029. Two-degree-of-freedom test comparing mean telomere length in skin
vs keloid and in skin vs average of K-1, K-2, and K-3: P = .14. Pairwise comparisons of
mean telomere lengths in skin vs K-1: P = .84, skin vs K-2: P = .11, skin vs K-3: P =
.012, skin vs keloid: P = .14, K-1 vs K-2: P = .023, K-1 vs K-3: P = .003, and K-2 vs
K-3: P = .25.
Although the 2-df test comparing mean telomere length in skin versus keloid and in
skin versus average of keloid 1, keloid 2, and keloid 3 was not signiﬁcant (P = .14), a
simpler model with a covariate for skin versus keloid, treating the keloid measurements as
indistinguishable,allowedustodoamorepowerful1-df comparisonofskinversuskeloids,




The runaway growth that forms a keloid is poorly understood, but the present study indi-
cates that it might be linked to telomere dynamics in the growing keloid. In spite of the
proliferative activity necessary to sustain keloid growth, telomere length in the keloid mass
is not shorter than that in the adjacent normal skin.
Figure 2 underscores the impact of somatic cell proliferation on telomere length,
as it shows that telomere length is considerably longer in subcutaneous fat than telom-
ere length in skin and leukocytes. While subcutaneous fat is poorly proliferative, skin
and the hematopoietic system are highly proliferative. Yet within the individual, telomere
length is highly correlated among different tissues, a ﬁnding also observed in previous
work in humans and macaques.12-15 We attribute this phenomenon to the lasting effect
of birth telomere length, which is highly synchronized among tissues within the new-
born but is highly variable across newborns.15 Thus, individuals with long telomeres in
one tissue are likely to have long telomeres in other tissues. That said, Figure 3 sug-
gests that the predilection to keloid formation does not relate to the individual’s telom-
ere length, since the study participants exhibited a wide range of telomere length that
overlaps that shown in other studies of individuals not selected on the basis of having
keloids.
A previous study observed no telomerase activity in keloids but concluded that keloid
telomere length was shorter than that in normal skin.16 We have conﬁrmed the lack of
telomerase activity in the keloid. However, our data indicate that telomere length in keloids
is not shorter than that of normal skin. In the previous study,16 keloids were obtained
from one group of individuals, while normal skin specimens were obtained from another
group. Given the large interindividual variation in age-adjusted telomere length, such a
design requires a large number of participants and that controls be carefully selected to
avoid bias. Our design has controlled for the high interindividual variation in telomere
length by comparing telomere length in the keloid with that in adjacent normal skin of the
same individual. In addition, the previous work showed in a subset of samples a strong
TRF signal that extended to the very low-molecular-weight region (Figure 2 in De Felice
etal16),whichsuggestscompromisedDNAintegrity.Wealsonotetheinadequateresolution
of the Southern blots in that study, shown in the illustrative Figure 2, and presume that the
molecular weight ladder in the ﬁgure may have been misplaced, as the mean TRF of normal
skin specimens appeared to be more than 1 kb shorter than the ref 6.1 molecular weight
marker.
Keloidscanattainalargemass,whichentailsconsiderableproliferationoftheircellular
elements. They are usually excised at a later phase of their growth after attaining a size that
causes disﬁgurement. Therefore, the inevitable conclusion of ﬁndings that telomere length
in keloids is not shorter and in fact might be longer than in normal skin is that mechanisms
that prevent telomere shortening operate during keloid formation. Telomerase8 a n do nr a r e
occasions ALT10 are such mechanisms. It is unlikely that activation of the ALT pathway
explains the lack of telomere shortening in keloids, because this mechanism primarily
operatesinvariousformsofcancerandimmortalizedcelllines,whichoftendisplayaberrant
chromosomal conﬁgurations, genomic instability, and relatively short telomeres, which is
not the case for keloids. Given that we detected no apparent telomerase activity in mature
keloids, we hypothesize that telomerase activation is transient and primarily takes place
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during the early growth phase of keloids; by the time the keloid is excised, telomerase
activity is apparently repressed.
To underscore the difference between telomere dynamics in keloids versus cancer,
it is useful to compare the clonal evolution model of cancer (reviewed in Visvader and
Lindeman17) and the model we propose for keloids. The clonal evolution model posits that
mutated but preneoplastic cells with growth advantage undergo multiple divisions, which
cause progressive telomere attrition until critically shortened telomeres set the limit for
further replication. On a rare occasion, telomerase, or less frequently ALT, is activated
as the cells undergo complete neoplastic transformation. However, telomerase activation
rarely serves to elongate telomeres when cells undergo cancerous transformation; it just
prevents further shortening. The clonal evolution model thus predicts that cancer would
often display shorter telomeres than adjacent noncancerous tissue in concert with robust
telomerase activity.18-20
Our model for telomere dynamics in keloid presumes that telomerase is activated only
during the early phase of the abnormal wound healing that brings about the formation of
keloids, and perhaps other hypertrophic scars. In contrast to the scenario in cancer where
the activation of telomerase prevents further telomere shortening, telomerase activation in
normal(precursor)cellsoftheformingkeloidnotonlypreventstheshorteningoftelomeres
but also might elongate them. As the keloid mass increases in size, the stimulation of
telomerasegraduallydeclines,suchthatbythetimeoftheresectionofthekeloid,telomerase
activityisostensiblyundetectable.Inthiscontext,ourﬁndingthattelomerelengthisshorter
just under the epidermis than at the base of the keloid suggests that the formation of the
keloid proceeds from a growth zone under the epidermis toward the base. In this way, cells
at the base of the keloid are those formed shortly after the healing process has started, when
telomerase activity is presumably at its peak and their telomeres are, therefore, the longest.
In contrast, cells toward the surface of the keloid have been formed later in the phase of
wound healing when telomerase activity is progressively repressed and consequently their
telomeres are relatively shorter. In that light, it is noteworthy that keloid precursor cells
were recently isolated from the dermal layer of keloids and these cells display features of
stem cells, including telomerase activity.21 It would be of interest whether these cells are
more abundant at the epidermis/dermis boundary.
Compared to normal wounds or skin, keloids are highly enriched in growth factors,
extracellular matrix, and inﬂammatory cytokines such as IL-6 and TGFβ. And this altered
extracellular milieu might play a central role in keloid development.22 Some of these
cytokines have been implicated in regulating the activity of telomerase. For instance, IL-6
increases telomerase expression and activity in dermal progenitor cells, which is greater
in keloid-derived progenitor cells, compared with those derived from normal skin.21 High
IL-6 levels in keloid scars, combined with increased sensitivity to IL-6-induced telomerase
activity, could result in telomere elongation, which would explain why cells in keloids have
longer telomeres than cells in normal tissue.
In addition, keloid ﬁbroblasts might have an altered sensitivity to signaling by TGFβ,6
which induces trans-differentiation of ﬁbroblast to myoﬁbroblast.23 TGFβ is also a neg-
ative regulator of the expression of the catalytic subunit of telomerase hTERT24-27 and
it is plausible, therefore, that TGFβ-mediated hTERT repression progressively increases
as the keloid matures. Interestingly, in itself, inhibition of telomerase can induce trans-
differentiation of ﬁbroblasts into myoﬁbroblasts,28 which suggests that TGFβ-induced
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myoﬁbroblast differentiation might be mediated by hTERT inhibition. However, given that
myoﬁbroblasts are absent in keloids,23 despite the presence of high levels of TGFβ and
its receptors, cells in keloids might be less sensitive to TGFβ-induced telomerase inhibi-
tion and trans-differentiation. This would explain the higher abundance of progenitor cells,
longer telomeres, and absence of myoﬁbroblasts in keloids.
In conclusion, precancerous cells that ultimately become cancerous already display
short telomeres before telomerase activation, which serves to prevent further telomere
erosion upon malignant transformation. We propose that in contrast, the abnormal wound
healing process that promotes keloid formation starts with normal cells, perhaps mes-
enchymal stem cells, in which telomerase “hyperactivation” not only prevents telomere
shortening due to replication but might even elongate telomeres. This phenomenon would
sustain the growth of the keloid at the early phase of its formation, but telomerase activity
is repressed once the keloid is well-formed.
On the basis of these considerations, we propose that telomerase activation might be
targeted in a deliberate effort to prevent or attenuate keloid growth through topical and
intraincisional application of antitelomerase compounds. Telomere length in normal skin
of young adults is generally long enough to enable sufﬁcient number of replication before
critically shortened telomere length might compromise replication. That said, the topical
and intraincisional application of antitelomerase compounds should be closely monitored
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